Science Explorer Interactive view Map
Company · Marlborough · United States

Sumitomo Dainippon Pharma (United States)

In research, Sumitomo Dainippon Pharma (United States) stands highest in Physical Sciences (#14,255 of 21,541 worldwide), over all time.

ds-pharma.com/index.htmlROR OpenAlex
World rank, all time
#19,823
of 42,892
Rank in United States
#4,288
of 8,685
Research works
402
▲ 41% vs 2013–17
Citations
7.3k
18.2 per fractional work
Top-10% rate
5.9%
record average 16.5%
Open access
66%
world 28%

What is Sumitomo Dainippon Pharma (United States) known for in research?

The fields where it stands highest, over all time, ranked among every institution above the floor in each field.

FieldWorld rankWhere that sitsTop-10% rateWorks
Physical SciencesDomain #14,255 of 21,541 7.5%189

Each strip is that field’s whole ranked pool, with the notch where Sumitomo Dainippon Pharma (United States) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.10× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 3.20× its world share, 9 worksBiochemistry, Geneti…Immunology and Microbiology: 6.42× its world share, 4 worksImmunology and Micro…Neuroscience: 3.79× its world share, 3 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 7.04× its world share, 1 worksPharmacology, Toxico…Chemistry: 1.24× its world share, 1 worksChemistryComputer Science: 0.09× its world share, 0 worksComputer ScienceEarth and Planetary Sciences: 0.10× its world share, 0 worksEarth and Planetary …Engineering: 0.11× its world share, 1 worksEngineeringEnvironmental Science: 0.10× its world share, 0 worksEnvironmental ScienceMaterials Science: 0.15× its world share, 0 worksMaterials ScienceMathematics: 0.74× its world share, 0 worksMathematicsDentistry: 0.63× its world share, 0 worksDentistryHealth Professions: 0.58× its world share, 1 worksHealth ProfessionsMedicine: 2.44× its world share, 26 worksMedicineNursing: 0.31× its world share, 0 worksNursingVeterinary: 4.51× its world share, 0 worksVeterinaryArts and Humanities: 0.11× its world share, 0 worksArts and HumanitiesBusiness, Management and Accounting: 0.97× its world share, 2 worksBusiness, Management…Decision Sciences: 0.38× its world share, 0 worksDecision SciencesEconomics, Econometrics and Finance: 1.46× its world share, 2 worksEconomics, Econometr…Psychology: 0.30× its world share, 0 worksPsychologySocial Sciences: 0.29× its world share, 2 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 7.0×. Every wedge is a field page.

Who are the top researchers at Sumitomo Dainippon Pharma (United States)?

Ranked on the composite score, Antonio Castagna lead among researchers whose main affiliation is Sumitomo Dainippon Pharma (United States).

  1. 1 Antonio Castagna United States · #1,444,029 worldwide 25 citations · 16 works
All ranked researchers at Sumitomo Dainippon Pharma (United States)

Which keywords describe research at Sumitomo Dainippon Pharma (United States)?

By fractional works in 2022–2025, weighted toward what it does more of than the world: Metabolic Syndrome, Cancer Therapy, Antipsychotic Drugs, Neurocognitive Deficits, Innate Immunity, Treatment Guidelines, Inflammation and Financial Performance.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Metabolic Syndrome4▲ 9.2×6 topics
  2. Epidemiology3▲ 1.52×10 topics
  3. Inflammation3▲ 2.5×14 topics
  4. Cancer Therapy3▲ 8.6×6 topics
  5. Antipsychotic Drugs2▲ 115×1 topic
  6. Neurocognitive Deficits2▲ 115×1 topic
  7. Oxidative Stress2▲ 2.6×9 topics
  8. Cancer2▲ 2.8×8 topics
  9. Financial Performance2▲ 5.8×3 topics
  10. Innate Immunity2▲ 10×5 topics
  11. Neurological Disorders2▲ 5.8×6 topics
  12. Quality of Life2▲ 2.3×6 topics
  13. Corporate Governance2▲ 4.2×3 topics
  14. Immunotherapy2▲ 4.0×5 topics
  15. Prognostic Factors2▲ 6.6×4 topics
  16. Treatment Guidelines2▲ 14×3 topics
  17. Tumor Microenvironment2▲ 6.5×5 topics
  18. Urinary Incontinence2▲ 37×2 topics
  19. Depression2▲ 3.2×7 topics
  20. Genetic Mutations2▲ 6.3×5 topics
  21. Genetic Variation2▲ 13×3 topics
  22. Cognitive Function1▲ 15×4 topics
  23. Genetics1▲ 3.8×5 topics
  24. Neurobiology1▲ 10×4 topics
  25. Stress1▲ 7.0×3 topics
  26. Benign Prostatic Hyperplasia1▲ 74×1 topic
  27. Lower Urinary Tract Symptoms1▲ 74×1 topic
  28. Parkinson's Disease1▲ 9.6×6 topics
  29. Cell Signaling1▲ 15×5 topics
  30. Hormone Therapy1▲ 27×3 topics
  31. Neurodegeneration1▲ 7.3×4 topics
  32. Prevalence1▲ 5.6×3 topics
  33. Signal Transduction1▲ 15×2 topics
  34. Clinical Guidelines1▲ 6.9×3 topics
  35. Hematopoietic Stem Cells1▲ 24×2 topics
  36. Surgical Treatment1▲ 11×2 topics
  37. Biosimilars1▲ 92×1 topic
  38. Immunogenicity1▲ 43×1 topic
  39. Neuroimaging1▲ 7.1×3 topics
  40. Proteasome Inhibitors1▲ 26×2 topics

Which research topics does Sumitomo Dainippon Pharma (United States) publish most on?

By volume in 2022–2025: Schizophrenia research and treatment, Urinary Bladder and Prostate Research, Biosimilars and Bioanalytical Methods and Bipolar Disorder and Treatment.

Schizophrenia research a…2Schizophrenia research and treatment: 2 fractional worksUrinary Bladder and Prostate Research: 1 fractional worksBiosimilars and Bioanalytical Methods: 1 fractional worksBipolar Disorder and Treatment: 1 fractional worksNeurotransmitter Receptor Influence on Behavior: 1 fractional worksUbiquitin and proteasome pathways: 1 fractional worksEndometriosis Research a…1Endometriosis Research and Treatment: 1 fractional worksParkinson's Disease Mechanisms and Treatments: 1 fractional worksAcute Myeloid Leukemia Research: 1 fractional worksRNA regulation and disease1RNA regulation and disease: 1 fractional works
Psychiatry and Mental healthUrologyImmunologyCellular and Molecular Neuroscience4 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 Schizophrenia research and treatment Psychiatry and Mental health 2 works
  2. 2 Urinary Bladder and Prostate Research Urology 1 works
  3. 3 Biosimilars and Bioanalytical Methods Immunology 1 works
  4. 4 Bipolar Disorder and Treatment Psychiatry and Mental health 1 works
  5. 5 Neurotransmitter Receptor Influence on Behavior Cellular and Molecular Neuroscience 1 works
  6. 6 Ubiquitin and proteasome pathways Molecular Biology 1 works
  7. 7 Endometriosis Research and Treatment Reproductive Medicine 1 works
  8. 8 Parkinson's Disease Mechanisms and Treatments Neurology 1 works
  9. 9 Acute Myeloid Leukemia Research Hematology 1 works
  10. 10 RNA regulation and disease Molecular Biology 1 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available65.7%not open34.3%

World: 28% of research is openly available.

with international co-authors44.9%domestic only55.1%

World: 19% is written across borders.

How has Sumitomo Dainippon Pharma (United States)'s research output changed?

Output in 2018–2022 was 41% higher than in 2013–2017.

1990200020102020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Marlborough

All research institutions in Marlborough

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.